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Over the past decades, thermoablative techniques for the therapy of localized tumors have gained importance in the treatment of
patients not eligible for surgical resection. Anecdotal reports have described spontaneous distant tumor regression after thermal
ablation,indicatingapossibleinvolvementoftheimmunesystem,henceaninductionofantitumorimmunityafterthermoinduced
therapy. In recent years, a growing body of evidence for modulation of both adaptive and innate immunity, as well as for the
induction of danger signals through thermoablation, has emerged. Induced immune responses, however, are mostly weak and
not suﬃcient for the complete eradication of established tumors or durable prevention of disease progression, and combination
therapies with immunomodulating drugs are being evaluated with promising results. This article aims to summarize published
ﬁndings on immune modulation through radiofrequency ablation, cryoablation, microwave ablation therapy, high-intensity
focused ultrasound, and laser-induced thermotherapy.
1.Introduction
The local application of high or low temperatures is
frequently used to induce protein denaturation, tissue
necrosis, and tumor destruction in order to curatively or
palliatively treat localized primary or secondary tumors [1].
Thermal ablative procedures in clinical practice comprise
radiofrequency (RF) ablation, microwave ablation therapy
(MWA), high-intensity focused ultrasound (HIFU), and
laser-induced thermotherapy (LITT) with the use of high
temperatures, as well as cryoablation with induction of low
temperatures. Primarily all these techniques were applied for
the palliative treatment of patients not eligible for surgical
resection or frail patients with a reduced functional reserve
capacity and many comorbidities [2, 3]. Local thermal
ablative methods present several advantages as compared
with surgery which include less damage to surrounding
healthy tissue, greater patient comfort, for example, less
pain and limitation in exercise due to wound healing,
improved cosmetic results, and—in times of critical ﬁnancial
situations in the medical facilities—reduced cost and shorter
periods of hospitalization [2, 4]. For selected patients, local
thermoablative techniques have similar clinical outcomes as
compared with historical controls of surgical resection [5–
8]. However, except for early hepatocellular carcinoma, no
largerandomizedclinicaltrialhasbeenperformedtodirectly
compare thermoablation and surgical resection so far [9].
In clinical routine, thermal ablation techniques have gained
further importance in the treatment of small tumors as an
alternative to surgical resection. Their application is limited
by the size of the tumor lesions since large tumors (>4cm)
require more expanded treatment with an increased rate of
complications and local recurrence [10, 11].
The choice of the most suitable thermal ablation modal-
ity depends on diﬀerent premises. Tumors located in tissues
with a high impedance like lung or bone can be better2 Clinical and Developmental Immunology
treated with cryoablation or MWA [12–14]. Other factors
for the assignment to an ablation modality depend on
patient characteristics and comorbidities, on the physician’s
choice and availability of a certain method in a respective
hospital, as well as on tumor location and relative position to
other anatomic structures [1]. The clinical indications and
characteristic features of each technique are summarized in
Table 1.
The concept of thermal treatment for cancer is not
new. The ﬁrst patients with cerebral tumors were already
treated with RF ablation in the early 20th century, but
it took until the 1990s for RF ablation to become an
accepted, commonly used treatment option for primarily
unresectable tumor lesions in liver, kidney, bones, and lung
[15]. During RF treatment, one or more RF applicators are
placed in the target tissue and high-frequency alternating
current is generated, leading to frictional heating above 60◦C
up to 100◦C inducing coagulative necrosis [2, 16]. Higher
temperatures would result in desiccation and subsequent
increaseintissueimpedancewhichlimitsfurtherconduction
of electricity into the tissue [12]. Recent studies have shown
that the clinical outcome after RF ablation is comparable
or even better in comparison to that of surgical resection.
Consequently, RF ablation is currently being discussed as
a possible new standard for elimination of metastatic liver
lesions and oligofocal hepatocellular carcinoma (HCC) [5,
8, 17] and further as a curative treatment option in HCC
and metastatic stages of colorectal carcinoma (CRC) when
combined with surgery [18, 19]. Early-stage non-small cell
lung cancer (NSCLC) can also be successfully treated with
RF ablation. However, retrospective comparative analyses of
survival have shown a strong tendency to increased survival
beneﬁts for NSCLC patients treated with surgery compared
to RF ablation (46 versus 33 months, P = 0.054) [20],
limiting the application of RF ablation to patients with
contraindications against surgery.
MWA represents a relatively new technique using elec-
tromagnetic waves to induce high temperatures of up to
more than 100◦C. Here also, an active microwave antenna
is placed into the tumor. Since MWA does not require the
conductofelectriccurrent,temperaturesabove100◦Cdonot
result in a decline of therapeutic eﬃcacy [12]. This method
could therefore be eﬀectively applied in tissues with higher
impedance like lung and bone [12]. In humans, MWA is
currently mainly applied for the treatment of HCC [21, 22].
During HIFU, ultrasound beams of high energy are
applied to focus acoustic energy on a well-deﬁned region
inducing tissue vibration. Although single ultrasound beams
can penetrate tissue without causing signiﬁcant heat,
focussing beams from multiple directions into a selected
region results in a temperature rise to over 60◦Ca n d
subsequently in coagulative necrosis [23, 24]. HIFU also
induces acoustic cavitation which represents an additional
mechanical mechanism of tissue destruction. Acoustic cav-
itation (the expansion and contraction of gaseous nuclei
in cells through acoustic pressure) leads to collapse of
mitochondria, endoplasmic reticulum, as well as nuclear and
cell membranes [25]. This procedure is the only noninvasive
thermal technique and allows real-time imaging of the
treatment progress by ultrasound (US) [25]. However, the
clinical application of HIFU is limited since the size of the
multidirectional ultrasound focus is conﬁned by technical
boundaries and a treatment time as short as possible is
required for an accurate ablation [24]. HIFU has been
applied for the treatment of breast, liver, pancreas, kidney,
bone, prostate, and soft-tissue tumors [25–27].
Laser ﬁbers placed into a tumor lesion are used for laser
ablation where photon energy conduction induced heating
can reach temperatures of over 50◦C. The tissue penetration
depth of laser light is only 0.4mm which implies that
multiple laser ﬁbers have to be positioned into a tumor to
ensure optimal tissue destruction [28]. However, this limited
penetration can facilitate the monitoring and accuracy of
the ablation. This technique is experimentally used for the
treatment of breast, brain, liver, bone, and prostate tumors
[29, 30]. More extensively used is the clinical exertion of
laser photocoagulation in retinal diseases, here also leading
to retinal scarring [31].
In contrast to all the techniques mentioned above,
cryoablation utilizes not high, but extremely low temper-
atures that sink to −160◦C[ 32]. Cryoablation involves
the evaporation of liquid gases and is a purely thermal
process which does not require application of electrical
current, leading to a broader applicability in high impedance
tissues like lung or bone. The extent of tissue destruction
can be easily monitored by direct monitoring of ice-ball
formation with all conventional imaging modalities [1].
Cryoablation is used in broad clinical application, even for
the treatment of retinoblastoma in children [33]. In 1–6% of
cases cryoablation causes a systemic inﬂammatory response
syndrome (SIR), termed as the cryoshock phenomenon which
represents a potentially life-threatening complication [34–
38] and limits its clinical application, especially for liver
tumors [39].
The observation that spontaneous regression of untreat-
ed tumors can occur after thermoablation of distant tumor
masses may indicate an involvement of immune activation
upon thermoablation [39–42]. The initiation, maintenance,
and termination of an eﬀective antitumor immune response
requires a complex interplay between cellular (immune cells
includingeﬀectorandregulatorysubsets)andhumoralcom-
ponents(cytokines,chemokines,antibodies).Variousconsti-
tutive or inducible danger signals released by injured cells are
known to play a determinant role in alarming the immune
system against self-damage. In this danger model, cells dying
by physiological processes such as apoptosis will be rapidly
eliminated and ignored by the immune system whereas
necroticcellsreleasingtheircontentintheextracellularspace
will trigger an immune response [43, 44]. In particular,
heat shock proteins (HSP) constitute a group of molecular
chaperones which stimulate the maturation of dendritic cells
(DC) and carry antigenic peptides from their cells of origin
inducing subsequent priming of antigen-speciﬁc T cells [45–
48]. Local ablative treatment induces necrosis which may
naturally modulate all of these parameters by inducing
inﬂammatoryprocessesﬁnallyleading tothe development of
an antitumor speciﬁc immune response. A growing series of
reports describing inﬂammatory responses, antigen releaseClinical and Developmental Immunology 3
Table 1: Thermal ablative methods in clinical use for the treatment of cancer and described eﬀects on the immune system.
Immune Modulation
Treatment Indication Characteristics/principle Component Eﬀect Ref. Species
Radiofrequency Clinical indication: primary and Mechanism: application of Cytokines + [51–54]H u m a n
(RF) ablation secondary malignancies in liver, alternating RF current through tip Danger + [55–61] Animal
kidney, lung, and bone applicator placed around and in signals + [62, 63]H u m a n
[2, 8, 17, 49] tumor tissue resulting in heat and Granulocytes + [64, 65] Animal
coagulative necrosis [54, 66]H u m a n
Experimental application: tumors NK cells + [61] Animal
of the breast [50] Approach: percutaneous, open, + [67]H u m a n
and intraoperative Monocytes/ + [66] Animal
Macrophages
Image guidance: US, CT, and MRI DC + [68, 69] Animal
[51]H u m a n
Tc e l l s ∗ + [49, 57, 65,
68–74]
Animal
+[ 70,75–78]H u m a n
Treg − [54]H u m a n
Bc e l l s + [ 75]H u m a n
Antibodies∗ +[ 78]H u m a n
Cryoablation Clinical indication: primary and Mechanism: application of cold Cytokines + [39, 83] Animal
secondary malignancies in liver, through gaseous evaporation at + [36, 84, 85]H u m a n
kidney, and prostate, as well as the tip of a cryoprobe. Repetitive Danger ?
dermatologic and ophthalmologic freezing and thawing cycles lead to signals
tumors [4, 33, 79, 80]. direct cellular damage through ice Granulocytes + [86] Animal
crystals, vascular and endothelial NK cells + [83] Animal
Experimental Application: tumors injury, and eventually thrombosis + [87]H u m a n
of the breast [81]. and ischemia [79, 82] resulting in Monocytes/ + [86, 88] Animal
coagulative necrosis and apoptosis Macrophages
at the ablation margin DC + [69] Animal
Tc e l l s + [38, 69, 79,
83, 89–98]
Animal
Approach: percutaneous, open, + [85, 87,
99–102]
Human
intraoperative
Treg +[ 103, 104] Animal
− [105]H u m a n
Image guidance: US, CT, and MRI B cells + [91] Animal
Antibodies∗ + [86, 106–
113]
Animal
+ [41, 87,
114–116]
Human
Microwave Clinical indication: mainly used for Mechanism: application of Cytokines ? [117] Animal
ablation therapy treatment of HCC, but also other microwaves through tip applicator Danger +
(MWA) primary and secondary leading to coagulative necrosis signals
malignancies of the liver [21, 22][ 21]G r a n u l o c y t e s ?
NK cells + [118] Animal
Approach: percutaneous, open, + [119]H u m a n
and intraoperative Monocytes/ + [119]H u m a n
Macrophages
DC ?
Image guidance: US, CT, and MRI T cells + [118] Animal
+ [22, 119,
120]
Human
Treg ?
Bc e l l s + [ 22]H u m a n
Antibodies ?4 Clinical and Developmental Immunology
Table 1: Continued.
Immune Modulation
Treatment Indication Characteristics/principle Component Eﬀect Ref. Species
High-intensity Experimental application: primary Mechanism: application of focused Cytokines ?
focused and secondary malignancies in ultrasound beams of Danger + [122]H u m a n
Ultrasound breast, liver, pancreas, kidney, high-intensity resulting in signals
(HIFU) bone, prostate, and soft-tissues- coagulative necrosis Granulocytes ?
tumors [121]N K c e l l s + [ 123]H u m a n
Monocytes/ ?
Approach: noninvasive Macrophages
DC ?
Image guidance: noninvasive Tc e l l s + [121,
124]
Animal
real-time US
+ [27, 125,
126]
Human
Treg ?
Bc e l l s + [ 27]H u m a n
Antibodies ?
Laser induced Clinical indication: broadly applied Mechanism: placement of multiple Cytokines + [130]H u m a n
thermotherapy for photocoagulation in retinal simultaneous ﬁred laser ﬁbers into Danger + [131] Animal
(LITT) disease [127], primary, and a tumor resulting in coagulative signals
secondary malignancies of the necrosis [129]G r a n u l o c y t e s
liver [128]
NK cells ?
Approach: percutaneous Monocytes/ ? Experimental application: primary
Macrophages and secondary malignancies of the
DC ? breast, brain, bone, and prostate
Image guidance: MRI, CT, and US T cells + [128,
132]
Animal
[129]
Treg ?
Bc e l l s ?
Antibodies ?
Asterisks indicate allocation of T-cell or antibody responses to deﬁned antigens.
Ref., reference number.
and uptake by professional APC and antitumor adaptive
immunity shows that this can indeed be the case. This
review aims to summarize ﬁndings on the modulation of the
immune system through high- or low- temperature-induced
thermal tissue ablation of cancer in animal tumor models
and cancer patients. The respective techniques are presented
in the order of common clinical use.
2. RadiofrequencyAblation
RFablation has the broadestapplication in cancertreatment.
It is therefore not surprising that most recent data relating to
the activation of the immune system through thermoabla-
tion have been obtained using this method (Table 2).
2.1. Cytokines and Stress Response. Several groups have
evaluated the systemic release of cytokines, chemokines,
and various stress factors after RF ablation. Serum levels of
proinﬂammatory cytokines like interleukins IL-1β,- 6 ,a n d
-8, as well as TNF were found to be either increased [51–54]
or unchanged [133, 134]. In general, changes were modest
and transient (several hours to days after ablation) [38, 52,
53, 134]. Moreover, IL-10 could be elevated in the serum
postinterventionally [54, 133]. Over all, no case of severe
SIRwithmultiorganfailureandcoagulopathy,butsigniﬁcant
increases in body temperature, mean arterial blood pressure,
and concomitantly increased serum levels of adrenaline, nor
adrenaline or C-reactive protein (CRP) have been reported
shortly after RF ablation [53, 54, 133, 134].
In murine models, RF ablation induced strong upreg-
ulation of mRNA and/or protein levels of HSP-70, HSP-
90, and glycoprotein 96 (gp96) as well as translocation of
nuclear high-mobility group protein B1 (HMGB1) into the
cytoplasm of tumor cells and into the intercellular space
[55–57]. More speciﬁcally, increased HSP-70 expression was
shown to occur at the margin of the ablation zone, the so-
called transition zone, both in animals [55, 58, 59] and in
human liver cells in vivo [62]. The time frame of maximal
HSP-70 expression is described to be no more than 24 hours
afterablation [56,60,62], the protein remaining upregulated
in the necrosis surrounding tissue three days after RF
ablation [61]. Several factors may inﬂuence local expression
of heat shock proteins after RF: in rats receiving thermal
ablation in diﬀerent zones of the liver, the degree of HSP-
70 expression was observed to be dependent on the relative
spatial position of the ablated area to larger liver vessels
since the blood stream of these vessels can nourish adjacent
cells preserving cellular metabolism and, hence, expressionClinical and Developmental Immunology 5
Table 2: Studies reporting immune modulation in cancer patients and animal models treated with RF ablation.
Species Tumor Model Immunologic eﬀect References
Human HCC (n = 1) HSP-70, HSP-90 (cytoplasm, membrane)↑ [62]
HCC (n = 8) Activation of myeloid dendritic cells (blood) [51]
IL-1β, TNF (serum)↑
HCC (n = 20) CD4+ and CD8+ cells (blood)↑ [70]
CD3−CD56+,C D 5 6 +CD16+ cells (blood)↑
Activity of tumor-speciﬁc T cells↑
HCC (n = 37) CD3−CD56dim cells (blood)↑ [67]
Activity of CD3−CD56dim cells↑
HCC (n = 20) Tumor-antigen speciﬁc T cells (blood)↑ [77]
RCC (n = 6) CD3+HLA-DR+,C D 4 + and CD8+ cells (blood)↑ [71]
CD56+CD16+cells (blood)↓
L i v e rm e t a s t a s e s( n = 8) Neutrophils (blood)↑ [66]
HCC (n = 4)
L i v e rm e t a s t a s e s( n = 6) CD4+ and CD8+ cells (blood)↑ [76]
HCC (n = 6)
Liver metastases of CRC IL-6 (serum)↑ [52]
(n = 10)
L i v e rm e t a s t a s e s( n = 9) IL-6 (serum)↑ [53]
HCC (n = 2)
Liver metastases (n = 13) CD4+ cells (blood)↓ [75]
HCC (n = 4) MUC-1 speciﬁc T cells (blood)↑
B cells (blood)↑ (only in metastatic cancer
patients)
Traﬃcking of CD62L+ T cells into tissues
Lung metastases (n = 4) IL-8, MIP-1α, MIP-1β (serum)↑ [54]
NSCLC (n = 10) IL-10 (serum)↑
CD4+CD25+Foxp3+ cells (blood)↓
Neutrophils (blood)↑
Liver metastases (n = 13) IL-6 (serum)↑ [133]
HCC (n = 4) IL-10 (serum)↑
Metastases (n = 29) ± chemotherapy CD4+ and CD8+ responses against tumor-speciﬁc [78]
Primary tumors (n = 26) antigens (blood)↑
Metastases (n = 16) Tumor-speciﬁc antibodies (serum)↑
HCC (n = 4) HSP-70 (serum)↑ [63]
RCC (n = 2)
Mouse CRC CT26 hEpCam ± huKS-IL2 Antitumor activity (splenocytes)↑ [74]
(BALB/c) Tumor growth (distant tumor)↓
Tumor growth (rechallenge)↓
C26 CD4+ cells (perinecrotic)↑ [65]
Neutrophils (perinecrotic)↑
Neutrophils and lymphocytes (distant
metastases)↑
HCC BNL ± CCL3 CD11c+ cells (blood)↑ [73]
CD11c+ cells (tumor)↑
CD4+ and CD8+ cells (tumor)↑
Tumor-speciﬁc cells (tumor)↑
Tumor growth (distant tumor)↓
Tumor growth (rechallenge)↓6 Clinical and Developmental Immunology
Table 2: Continued.
Species Tumor Model Immunologic eﬀect References
Mouse Melanoma B16-OVA ± CTLA4-mAb CD8+ tumor-antigen speciﬁc T cells (blood)↑ [72]
(C57BL/6) ± Treg depletion Tumor growth (rechallenge)↓
B16-OVA ± CTLA4-mAb Antigen loaded DC, DC maturation (draining [69]
lymphnodes)↑
Tumor growth (rechallenge)↓
B16-OVA ± DC HSP-70, gp96 (tumor)↑ [57]
HMGB1 (tumor)↑
CD8+ tumor-speciﬁc T cells (spleen, draining
lymph nodes)↑
Local recurrence↓
Tumor growth (rechallenge)↓
Urothelial carcinoma MB49 ± DC CD4+,C D 8 + antitumor responses (splenocytes)↑ [49]
CD11c+cells (tumor)↑
Tumor growth (rechallenge)↓
Mouse CRC HT29 HSP-70 mRNA (cytoplasm)↑ [56]
(NIH (S)-nu)
Rabbit Hepatoma VX2 Lymphocytes, plasma cells, and neutrophils [68]
(tumor)↑
Tumor-speciﬁc T cells (blood)↑
Rat (Fisher) Mammary MatBIII CD161+ cells (tumor-surrounding tissue)↑ [61]
HSP-70 (tumor-surrounding tissue)↑
R3230 ± liposomal HSP-70 (around central coagulation zone)↑ [59]
doxorubicin
Rat (rNU) Hepatoma SK-HEP-1 HSP-70, HSP-90 (cytoplasm, membrane)↑ [55]
of HSP in these cells [60]. Further experiments in nude rats
transplanted with human HCC also suggested a correlation
between applied energy and level of expression of HSP-70
and -90 [55]. As we recently described, a signiﬁcant systemic
release of HSP-70 into the serum can also be detected one
day after treatment in RF-treated cancer patients, but serum
levels did not correlate with ablation volumes, histological
tumor type, and other clinical or laboratory parameters [63].
2.2. Cellular Immunity
2.2.1. Changes in Peripheral and Intratumoral Immune Cell
Subsets. Postinterventional changes in peripheral leukocyte
subsets have been observed by several groups and taken
as evidence for the immune modulatory eﬀect of RF
ablation. Of note, antibody tools for cell subset identi-
ﬁcation, timepoints of observation, and patient cohorts
diﬀered between published studies. A decrease of circulating
CD4+CD25+Foxp3+ regulatory T cells (Treg)w a so b s e r v e d
in patients 1 month after RF ablation of lung nodules
[54]. In another study including 20 HCC patients, no
signiﬁcant changes in T-cell subsets were detected 1 month
after RF (na¨ ıve or memory CD4+,C D 8 +) while increased
percentages of activated T cells and circulating NK cells
were noted in randomly selected patients from the study
cohort [70] .T h es a m eg r o u pl a t e rd e s c r i b e dam a r k e d
expansion of CD3−CD56dim eﬀector NK cells 1 week and
4 weeks after treatment [67]. Matuszewski and colleagues
evaluated lymphocyte subpopulations after RF ablation of
renal cell carcinoma (RCC) in 6 patients and found a
globally increased proportion of activated T cells in the
majority of patients (CD3+HLA-DR+) whereas eﬀects on
CD4+,C D 8 +, and NK (CD56+CD16+) cells varied among
individuals and at diﬀerent timepoints [71]. In patients with
colorectal liver metastases, but not with HCC, a transient
decreaseinCD3+CD4+ Tcellswasnotedshortly(day2)after
treatment [75]. Although these and further observations
are heterogenous, they collectively suggest an impact of
RF ablation on various peripheral cell subsets, including
Ta n dN Kc e l l s[ 61], but also neutrophils, monocytes, B
lymphocytes, and even DC [51, 54, 66, 75].
The assessment of tumor-inﬁltrating cells before and
following RF ablation is intrinsically diﬃcult in patients and
available data have been obtained in various animal models.
Most reports describe inﬁltration of immune cells in the
transition zone hours to days after treatment. Granulocytes,
macrophages, plasma cells, DC, CD3+, and CD4+ cells were
found [49, 64, 68]. Interestingly, neutrophils and lympho-
cytes could also inﬁltrate distant, untreated metastases [65].
2.2.2. Antitumor Speciﬁc Responses. Few data addressing the
adaptive immune response to tumors after RF ablation are
available.
In a transplant-tumor model of VX2-hepatoma, rabbits
were randomly assigned to treatment with RF ablation or
to observation. Two weeks after RF ablation, the activationClinical and Developmental Immunology 7
of tumor-lysate speciﬁc T cells was detected and persisted
over a postinterventional observation period of 6 weeks [68].
Animals in the RF-treated group had a signiﬁcant survival
increase [68].
Antigen-speciﬁcity of RF-induced antitumor T-cell
responses was investigated in several reports. Dromi and
coworkers used a murine urothelial carcinoma expressing
the male minor histocompatibility antigen HY which was
inoculated to female mice. T-cell responses against MHC-
class I and class II HY-derived epitopes were signiﬁcantly
increased in the group of mice having received tumor
RF ablation as compared to control animals. This was
accompanied by an enhanced control of tumor growth,
including upon rechallenge [49].
In a mouse model of OVA-expressing melanoma, adop-
tive transfer of splenocytes from RF-treated to na¨ ıve mice
led to a growth retardation of OVA+-, but not OVA−-tumors
after rechallenge, and to complete tumor elimination in
20% of the mice. The treatment could also induce long-
lasting immunity since RF-treated mice surviving the ﬁrst
tumor inoculation were completely protected after a second
challenge 70 days later [72]. Moreover, intratumor injection
of tagged-OVA led to antigen uptake and maturation of
CD11c+ cells in the tumor-draining lymphnode, albeit to
a lesser extent than after cryoablation which was directly
compared to RF ablation in this model [69].
In patients, HCC-reactive T cells were detected with
IFNγ ELISPOT in 4/20 patients before RF ablation upon
stimulation of PBMC with lysate of autologous tumor
cells obtained either before or after treatment. One month
after RF treatment, cellular reactivity was observed in 9/20
patients, strongly suggesting an in vivo immunization eﬀect
after RF-intervention [70]. Similar results were reported in
two further cohorts of HCC and CRC patients [76].
Three recent publications have addressed the antigen-
speciﬁcity of the RF-induced T-cell responses in patients.
Napoletano and colleagues detected an increased IFNγ
production upon stimulation with MUC-1-derived gly-
copeptides in 2 patients treated for liver metastases and also
an increase in circulating CD3−CD19+ B cells. However,
the speciﬁcity of antibodies was not studied [75]. Hiroishi
and coworkers investigated CD8+ T-cell responses against
MAGE-1, NY-ESO-1, and GPC3 antigens in patients with
HCC and found that antigen-speciﬁc T cells were already
detectable in samples obtained before RF ablation, and
increasedinapproximatelyhalfofthepatients[77].Recently,
we evaluated the occurrence of tumor-antigen speciﬁc T cells
or antibodies after RF ablation in 55 cancer patients and
found an increase in antigen-speciﬁc antibodies, and CD4+
or CD8+ T cells in several individuals receiving RF ablation
alone or shortly after chemotherapy [78].
2.2.3.CombinationTherapies. Alltheresultspresentedabove
show that RF ablation is able to induce tumor-directed
immunity; however, the observed therapeutic eﬀects are
limited. Combination therapies have therefore been already
tested in preclinical models, with the aim to enhance
antitumor responses and protection. For OVA-expressing
melanoma, CTLA-4 blockade or Treg depletion (with anti-
CD25 mAb) showed improvement in tumor control and
enhanced induction of OVA-speciﬁc CD8+ T cells whereas
CTLA-4 mAb application without RF ablation did not
mediate the same eﬀects [72].
The coadministration of the monocyte attracting
chemokine ligand 3 and inﬂammatory protein-1α
(CCL3/MIP-1α)[ 73], antibody-conjugated IL-2 [74]o r
even chemotherapy (liposomal doxorubicin) [59] also
enhanced the eﬀects of RF ablation. Finally, whereas
intratumor injection of unloaded DC did not synergize
with RF-treatment, application of tumor-lysate loaded
D Cw a sr e p o r t e dt oa b r o g a t et u m o rr e l a p s ei nm o s t
animals. Interestingly, while vaccination with DC alone was
ineﬀective with regard to survival beneﬁts, the combination
with RF ablation signiﬁcantly improved the survival of
tumor bearing mice [49, 57].
All these reports provide a strong rationale for testing
the combination of RF therapy with immune-modulating
agents in cancer patients. It has to be noted that—besides
RF ablation—many patients currently receive additional
therapies like chemotherapy which may also inﬂuence
the development of tumor-speciﬁc immune responses as
recently recognized [137].
2.3. Immune Response and Clinical Course. The relation-
ship between occurrence of antitumor immunity after RF
ablation and clinical outcome still remains elusive. In HCC
patients with induced tumor-speciﬁc T-cell reactivity after
RF ablation, the local- and distant-site recurrence was
similar [70]. In contrast, Hiroishi and colleagues observed a
correlation between the frequency of tumor-antigen speciﬁc
T cells and a favorable tumor-free survival in HCC patients
[77]. Here, it has to be noted that patients could additionally
receive transarterial chemoembolization (TACE). We have
recently observed a tendency to a better survival for patients
who presented with at least a twofold increase of HSP-70
in the serum one day after treatment [63]. Since patient
cohorts were small in all three studies, results need further
conﬁrmation.
3. Cryoablation
3.1. Special Premises of Cryoablation. While thermal tech-
niques utilizing lethal high temperatures have been so far
mostly described to stimulate immune responses, cryoab-
lation has been described to exert both stimulatory and
suppressive eﬀects on the immune system. These particular
features could be due to the speciﬁc physiological mech-
anisms of cold injury including (i) direct cellular damage
through formation of ice crystals, and (ii) vascular and
endothelial injury with potential ischemia [82]. Whereas
most other thermoablative techniques are believed to induce
essentially coagulative necrosis, apoptotic cells might be
also present at the outer rim of the ablation zone after
cryoablation. According to the danger model,a p o p t o t i cc e l l s
do not release their cellular content (antigens, HSP, and
HMGB1) and induce immunological tolerance [43, 44].8 Clinical and Developmental Immunology
It has been proposed that larger numbers of apoptotic
cells might cause tissue protection and lead to immuno-
suppression while larger numbers of necrotic cells could
serve as immunostimulators [4]. More recently, they showed
that the cryoablation modality itself, that is, rate of freeze,
inﬂuences both tumor growth and T cell recruitment [79].
Moreover, technique and rate of freezing cycles could play
a role in the precise mechanisms of the watershed between
immunosuppression and immunostimulation after cryoab-
lation [79]. However, this model is questioned by more
recent reports showing that apoptotic cells can also exhibit
signiﬁcant immunostimulatory capacity [138, 139]. One
other inﬂuential factor for these contradictory observations
could be the timepoint of immunomonitoring: early assess-
ment might miss immune activation and antitumor activity.
Interestingly, clinical improvement could be recorded rather
late after cryotreatment (up to 10 weeks) [140, 141]w h i c h
is in line with the new concept that assessment of tumor
response upon immunotherapy should be performed later
than after conventional cytostatic therapy [142].
Table 3 only presents recent immunological observations
of the past decade. Many observations reporting immuno-
suppression by cryoablation were made earlier and are
discussed below, but are not presented in the table.
3.2. Cytokines and Stress Response. Unlike the other ther-
moablative methods, cryoablation induces a cytokine release
syndrome (SIR—1–6.4% of all cases, with a mortality rate of
0.2–4%) [34, 35], assimilated to the cryoshock phenomenon
which is clinically manifested by thrombocytopenia, dis-
seminated intravascular coagulation (DIC), and pulmonary
failure [35–38]. Cryoshock is mainly limited to ablation of
hepatocytes [39]. In sheep and rats, the frequency of SIR cor-
related positively with the extent of cryoablated liver tissue,
animals with more than 35% of ablated tissue presenting an
elevated risk of SIR [37]. Moreover, cryoablation leads to
signiﬁcant increases of serum IFNγ TNF, IL-6, and IL-12,
but not IL-10 within several hours after intervention [36, 83,
84]. In a rat model, cytokine release after cryoablation, RF
ablation, and LITT was compared. Between 1 and 6 hours
after cryoablation, signiﬁcantly elevated serum levels of IL-
6 were observed. IL-10 serum levels were slightly, but not
signiﬁcantly elevated [38]. In patients, TNF and IFNγ could
remain elevated for up to four weeks [85]. In a model of
transgenic mice overexpressing HSP-70 only a slight increase
of HSP-70 expression could be observed which proved to be
tissue-protective against cryonecrosis in skeletal muscle cells.
Here, is has to be noted that no complete cryoablation, but
onlycryolesioningofskinandskeletalmusclewasperformed
[88]. To our knowledge, no data on HSP expression after
necrosis induction through cryoablation are available.
3.3. Antibodies. The earliest reports on immune modiﬁca-
tion after cryoablation described autoantibody production
against ablated normal and tumor tissues in rabbits and
monkeys, as well as in patients [41, 106–112, 114]. These
antibodies were essentially IgG and IgM in the serum
[41, 86, 114] and at the vicinity of the ablated lesion
mainly IgG and IgA [115] appearing within two weeks after
intervention [41, 86, 114]. In contrast, M¨ uller and colleagues
treated osteosarcoma in mice with cryoablation and found a
decrease of tumor-binding antibodies [113].
Another eﬀect of cryoablation was detected by Ravin-
dranath and colleagues who observed a release of ganglio-
sides into the circulation of CRC patients after cryoablation
but not after RF ablation or surgery. At the same time,
the group also described increasing titers of anti-ganglioside
IgM antibodies [116]. Since anti-ganglioside antibodies have
inhibitory eﬀects on primary tumors, such as the induction
of complement mediated killing [143]o ra p o p t o s i s[ 144],
production of antitumor antibodies might be one of the
mechanisms underlying the immune-mediated tumor rejec-
tion following cryoablation [116].
3.4. Cellular Immunity
3.4.1. Changes in Peripheral and Intratumoral Immune Cell
Subsets. In rats, signiﬁcantly elevated peripheral leukocyte
counts—especially CD3+ and CD4+ T cells—were detectable
between 1 and 14 days after intervention [38, 89]. In
humans, cryoablation led to an increase of circulating T
cells in few patients [99, 100]. In a randomized trial,
cryoablation—compared to conventional surgery—led to
increased numbers of helper T cells and activated T cells
[101]. In a cohort of patients with liver metastases, an
increase of the Th1/Th2 ratio was observed in the peripheral
blood [84] whereas Zhou and colleagues reported a decrease
of circulating CD4+CD25+Foxp3+Treg after cryolesioning of
HCC [105].
In tumor draining lymph nodes (TDLN), increased
cellularity was observed both in T-cell (paracortical) and
B-cell (germinal center) areas one week after treatment.
Immunologic activity could remain increased over a time
span of up to 10 weeks [90, 91]. Using a xenograft model
of human melanoma in nude mice, Gazzaniga and cowork-
ers further described a massive intravascular and peritu-
moral recruitment of leukocytes, essentially neutrophils and
macrophages after cryoablation [86]. In a mouse mammary
cancer model, the number of CD4+ T cells in TDLN
was augmented. Interestingly, CD4+CD25+Treg were more
numerous after low rate freeze [79].
3.4.2. Antitumor Speciﬁc Responses. Assessment of the
immune modulation by cryoablation has yielded contradic-
tory results. Older works have pointed out immunosuppres-
sive eﬀects: an increase of circulating immune eﬀector cells
was not of functional relevance for tumor rejection, rather,
tumor outgrowth and increased metastasis was promoted.
This indicated that cryoablation might mediate deleterious
eﬀects possibly by induction of suppressor T cells, today
referred to as regulatory T cells, as well as delayed develop-
ment of antitumor immunity [103, 104, 145]. In line with
these ﬁndings, Machlenkin and colleagues did not observe
cellular activation through cryotherapy as a monotherapy
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Table 3: Recent Studies reporting immune modulation in cancer patients and animal models treated with cryoablation.
Species Tumor Model Immunologic eﬀect References
Human CRC (n = 110) Gangliosides (GM2,G D 1a,G T 1b; serum)↑ [116]
Antiganglioside antibodies (serum)↑
HCC (n = 111) CD4+CD25+Foxp3+ cells (blood, ablation [105]
zone surrounding tissue)↓
Prostate (n = 20) IFNγ ↑, TNF (serum)↑ [85]
Tumor-speciﬁc T-cell responses (blood)↑
Prostate (n = 12) ± GM-CSF Tumor-speciﬁc T-cell responses (blood)↑ [85]
RCC (n = 6) + GM-CSF Tumor-speciﬁc T-cell responses (blood)↑ [87]
Tumor-speciﬁc antibodies (serum)↑
Liver metastases IL-6, TNF (serum)↑ [84]
(n = 12) Th1/Th2 ratio (blood)↑
CCC (n = 3)
Mouse (BALB/c) CRC Colon-26 ± krestin CD8+ antitumor T-cell reactivity (spleen) [94]
(↑)
Number of metastases↓
Colon-26 ± Treg Tumor-speciﬁc CD8+ T cells (spleen)↑ [96]
depletion ± DC + BCG Tumor growth (distant tumors)↓
Colon-26 ± Tumor-speciﬁc T cells (spleen, draining [97]
cyclophosphamide lymph nodes)↑
Tumor growth (rechallenge)↓
Mammary MT-901 IFNγ, IL-12 (serum)↑ [83]
Tumor-speciﬁc T cells (draining
lymph nodes but not in spleen)↑
NK cell activity (spleen)↑
Tumor growth (rechallenge)↓
T cells (draining lymph nodes)↑ [95]
Tumor-speciﬁc T cells (draining lymph
nodes)↑
Pulmonary metastases↓
Tumor-speciﬁc T cells (draining lymph [79]
nodes)↑
Pulmonary metastases (high-intensity
freezing)↓
Pulmonary metastases (low-intensity
freezing)↑
Melanoma B16-OVA ± imiquimod Tumor-speciﬁc T cell proliferation↑ [98]
Tumor growth (rechallenge)↓
B16-MO5 ± DC Tumor growth (rechallenge)↓ [92]
Mouse (C57BL/6) Melanoma B16-OVA ± DC maturation and antigen uptake [69]
CTLA4-mAb (TDLN)↑
Tumor growth (rechallenge)↓
B16-OVA ± CpG DC (TDLN)↑ [135]
CD4+,C D 8 + Tc e l l s( T D L N ) ↑
OVA-speciﬁc T cells (TDLN)↑
Tumor growth (rechallenge after
peritumoral CpG administration)↓
Mouse (NIH Melanoma IIB-MEL-J (human) Neutrophils (RB6-5CG+)[ 86]
(S)-nu) ± GM-CSF (tumor-surrounding tissue)↑
macrophages (F4/80+; tumor-surrounding
tissue)↑
DC (DEC205+; tumor-surrounding
tissue)↑10 Clinical and Developmental Immunology
Table 3: Continued.
Species Tumor Model Immunologic eﬀect References
Mouse (OT-I T cell Lung Lewis lung tumor Tumor-speciﬁc CD8+ T-cell [92]
receptor (Vα2/Vβ5) D122 ± DC proliferation↑
transgenic) Th1 responses↑
Tumor growth (lung metastases)↓
Rat (Wistar) Glioma C6 CD3+ and CD4+ T-cell percentages (blood)↑ [89]
CD4+/CD8+ ratio (blood)↑
(↑) Weak induction.
In contrast, other groups demonstrated immunologic
activation in cryotreated animals (Table 3). Kimura and
colleaguesfoundanincreasedcytotoxicactivityofperipheral
lymphocytes and splenocytes against a murine leukemia
virus-inducedlymphoma[146].Regressionofdistantmetas-
tases and resistance to tumor rechallenge was described by
Bagley and colleagues who found that splenic lymphocytes
isolated from sarcoma-bearing mice treated with cryoab-
lation exhibited signiﬁcantly increased cytotoxic activity
against sarcoma cells as compared to those obtained from
mice undergoing limb amputation [93]. Increased immuno-
logical activity could be delayed up to ten weeks after
intervention [140].
Urano and colleagues observed an increased activity
of tumor-speciﬁc cytotoxic T lymphocytes (CTL) seven
days after cryoablation in a mouse colon-carcinoma model.
These eﬀects were only observed after ablation of a single
nodule while ablation of several lesions abrogated immune-
related tumor regression. Here, a threshold of ablated tissue
volume that governed immune stimulation or suppression
was proposed [94]. Interestingly, tumor-speciﬁc eﬀectorcells
isolated from TDLN but not from the spleen or peripheral
blood secreted a higher amount of IFNγ (between days 3 and
7 after treatment) as compared to cells obtained following
surgical resection.
In an OVA-expressing melanoma model, den Brok and
colleagues observed an increase of antigen-loaded DC in
draining lymph nodes both after cryoablation and RF-
ablation. Of note, almost double as high cell numbers were
observed compared to the induction through treatment with
RF ablation [69]. Moreover, the numbers of inﬁltrating
lymphocytes in TDLN were increased. These lymphocytes
produced approximately 10-fold greater amounts of IFNγ
upon stimulation with irradiated mammary adenocarci-
noma cells after cryoablation than after surgical resection,
delayed tumor growth and reduced the number of pul-
monary metastases after adoptive transfer of TDLN cells
of the cryoablated tumor [95]. The protection against a
tumor rechallenge with B16-OVA cells was enhanced after
cryoablation (50% surviving mice after 70 days) compared
with the protective eﬀect observed after RF ablation (20%
surviving after 70 days) [79, 83, 95].
3.4.3. Combination Therapies. While Machlenkin and col-
leagues observed no clinical beneﬁt with cryoablation alone,
the combination with an intratumoral injection of immature
DC induced robust activation of CD4+ and CD8+ CTL
[92]. This synergistic eﬀect was further improved after
pretreatment with anti-CD4 or anti-CD25 mAb for Treg
depletion [96].
In an OVA-expressing melanoma model, CTLA-4 block-
ade and depletion of regulatory T cells could further
enhance cryoinduced tumor-speciﬁc T-cell responses [69].
Alternatively, concomitant injection of CpG 1668, a TLR 9
ligand, had a similar eﬀect on T-cell recruitment. The route
of adjuvant injection was crucial for immune induction,
peritumoral CpG application showing to be superior to
distant site. Although tumor growth was delayed after
combination therapy, survival beneﬁt was not superior to
treatment with cryoablation alone [135].
Conditioning with cyclophosphamide injected one day
before cryoablation led to increased IFNγ production of
tumor-antigen speciﬁc CD4+ T cells in a mouse colon
cancer model as detected in intracellular cytokine staining,
enhanced survival and even some complete remission. Three
out of four animals cured with the combination therapy also
survivedatumorrechallengewithnomacroscopicallyvisible
tumor upon autopsy [97]. Moreover, adoptive transfer of
spleen and lymph node cells from surviving mice led to
an improved survival in tumor-bearing mice. Depletion
experimentsshowedthatCD8+ eﬀectorswereresponsiblefor
tumor elimination indicating that immunological memory
had developed [97].
In the same OVA-expressing melanoma model used by
den Brok and colleagues, Redondo and coworkers observed a
clear survival advantage for mice treated with cryoablation
combined with repeated topical application of imiquimod
as an adjuvant indicating that TLR-7 activation can enhance
tumor-speciﬁc immune responses induced by thermal treat-
ment [98].
To sum up, all these reports suggest that combination
of cryoablation with check point blockade or immunoad-
juvants is a promising approach in the treatment of cancer
patients.
3.5. Immune Response and Clinical Course. In patients with
hormone refractory prostate carcinoma, a combination of
cryoablation with injection of GM-CSF as adjuvant was
evaluated. T-cell reactivity against autologous tumor tissue
lysates as determined in IFNγ ELISPOT was found to be
weakly increased after therapy, and no correlation could be
establishedbetweenthebreadthoftheimmuneresponseand
the clinical course as measured by analysis of PSA serum
levels [85, 102]. Also in a small cohort of patients with RCC,Clinical and Developmental Immunology 11
increased cytotoxic T-cell activity and increased antitumor
serum antibodies in selected patients were observed which
only weakly correlated with a favorable clinical response.
Here also, GM-CSF was applied as an adjuvant [87].
4. Microwave Ablation
As with RF ablation, microwave ablation therapy (MWA)
induces hyperthermia leading to coagulative necrosis. The
clinical application of MWA is, however, more limited than
the thermoablative methods discussed above and only few
groups have evaluated the immunomodulatory eﬀects of
MWA (Table 4).
4.1. Cytokines and Stress Response. MWA was described to
induce HSP-70 expression in normal kidney tissue lysates
obtained from treated rats, as detected with speciﬁc ELISA.
However, HSP-70 expression was signiﬁcantly lower upon
MWA as compared to animals treated with RF ablation and
cryoablation [117].
4.2. Cellular Immunity. In a mouse tumor model of HCC,
only 2/10 animals experienced tumor rejection upon rechal-
lenge after MWA, suggesting an existing but suboptimal
protective antitumor immunity [118]. However, the protec-
tive eﬀect could be improved by intratumoral coadminis-
tration of GM-CSF loaded microspheres, and even more by
intraperitoneal CTLA-4 blockade. The triple combination
not only led to rejection of newly inoculated tumors, but was
also eﬀective in the rejection of established distant tumors.
Splenocytes isolated from the treated mice killed hepatoma
cells in vitro, but not an unrelated tumor cell line. In vitro
depletion experiments using mAb could further show that
cytotoxicity was mediated by T cells (both CD4+ and CD8+)
and NK cells, conﬁrming that antitumor immunity was
induced upon combination therapy [118].
One month after MWA, 10 patients with hypersplenism
that had developed as a result of portal hypertension
exhibited a transient peripheral increase of T helper cells
(CD3+CD4+) and B cells, but not of cytotoxic (CD3+CD8+)
T cells [22] .I nal a r g e rc o h o r to fp a t i e n t ss u ﬀering from
HCC, immune cell inﬁltration was studied by immuno-
histochemistry analyses of biopsy tumor samples taken
e i t h e rb e f o r eo ra td i ﬀerent timepoints (3–30 days) after
MWA application. A markedly increased inﬁltration of
lymphocytes (predominantly CD3+ T cells, CD56+ NK cells,
andmacrophages,butnotofBcells)wasdetectedafterMWA
inside the ablated lesions, in the adjacent normal tissue and
in distant untreated lesions [119].
4.3. Immune Response and Clinical Course. The density of
inﬁltrates of lymphocytes, macrophages, and CD56+ cells
into MWA-treated liver tissue correlated inversely with the
risk of local recurrence [119].
Zhou and colleagues performed a phase I clinical study
in ten HCC patients with chronic hepatitis B by combining
localmicrowavetumorablationwithimmunotherapy,which
was applied at 3 timepoints, that is, on the day of the
MWA and then on days 11 and 100. Immature and mature
monocyte-derived DC loaded with autologous tumor lysate
were injected into the rim between the ablation zone and
normal liver parenchyma and into the groin lymph nodes,
respectively. Additionally, in vitro activated lymphocytes
were applied intravenously. A modest and transient eﬀect
on peripheral T-cell subsets (decrease of CD4+CD25high—
possibly Treg—and increase of CD8+CD28−—diﬀerentiated
CD8+ T cells—was reported one month after treatment
concomitant with a reduction in hepatitis B virus load
observed in some patients, but analyses of the antitumor
speciﬁc responses were not performed in this study. Of note,
this clinical setting does not allow determining whether
the observed eﬀects were due to the MWA itself, to the
immunotherapy regimen or to the combination of both
treatments [120].
5.High-IntensityFocused Ultrasound(HIFU)
Inadditiontomerehyperthermia,HIFUalsoexertsnonther-
mal mechanistic constraints (acoustic cavitation) on treated
tissues that might contribute to and modulate its eﬀects on
the immune system [122]( Table 5).
5.1. Cytokines and Stress Response. In breast cancer patients,
increased HSP-70 expression was detected on the cell mem-
brane of treated cancer cells. HSP expression was mainly
found in the central necrosis zone while only a few positively
stained cells were observed in the periphery [122].
5.2. Cellular Immunity
5.2.1. Changes in Peripheral and Intratumoral Immune Cell
Subsets. In patients with posterior uveal melanoma [125],
pancreatic carcinoma [123], osteosarcoma, HCC, and RCC
[126] that were treated with HIFU, increased percentages of
CD4+ T cells and a higher CD4+/CD8+ ratio were observed
[125, 126]. Another study observed only statistically signif-
icant higher NK cell percentages in the peripheral blood,
while other leukocyte subsets remained stable [123].
In human breast cancer specimens collected 1-2 weeks
after HIFU treatment, immunohistochemistry analyses
showed a signiﬁcant increase of T and B cells at the margin
of the ablated region as compared to HIFU-untreated tumor
samples. Interestingly, a subset of these cells were activated
(CD57+) and expressed perforin and granzyme B, indicating
the presence of activated cytotoxic eﬀectors [27].
5.2.2. Antitumor Speciﬁc Responses. In a model of exper-
imental neuroblastoma, reduced secondary tumor growth
after HIFU treatment was observed, although involvement
of immune cells was not evaluated further [136].
Zhang and coworkers immunized mice with a vaccine
consisting of a lysate of the H22 hepatoma cell line
either untreated or pretreated in vivo with HIFU. Ten
days after vaccination, animals received a subcutaneous
tumor challenge. Tumor growth was signiﬁcantly delayed in
mice vaccinated with previously HIFU-treated tumor cells.12 Clinical and Developmental Immunology
Table 4: Studies reporting immune modulation in cancer patients and animal models treated with MWA.
Species Tumor Model Immunologic eﬀect References
Human HCC (n = 82) CD3+ cells, CD56+ cells (treated and distant tumors)↑ [119]
CD68+ cells (treated and distant tumors)↑
HCC (n = 10) ± DC Phase I study: [120]
CD4+CD25high cells (blood)↓
CD8+CD28− cells (blood)↑
Mouse HCC Hepa 1–6 Activity of tumor-speciﬁc CD4+,C D 8 + cells (spleen)↑ [118]
(C57BL/6) ±GM-CSF NK1.1+ cells (spleen)↑
±
CTLA4-mAb
Tumor growth (rechallenge)↓
Table 5: Studies reporting immune modulation in cancer patients and animal models treated with HIFU.
Species Tumor Model Immunologic eﬀect References
Human Breast carcinoma (n = 23) HSP-70 (membrane)↑ [122]
Breast carcinoma (n = 48) CD3+,C D 4 +,C D 8 + cells (tumor)↑ [27]
CD20+ cells (tumor)↑
CD57+ cells (tumor)↑
Pancreatic carcinoma (n = 15) NK cells (blood)↑∗ [123]
Uveal melanoma (n = 5) CD4+ cells (blood)↑ [125]
Osteosarcoma (n = 6) CD4+ cells (blood)↑ [126]
HCC (n = 5)
RCC (n = 5)
Mouse (Ajax) Neuroblastoma C1300 ± adriamycin Tumor growth (rechallenge)↓ [136]
Mouse (C57BL/6J) HCC H22 ± DC Activation of CD8+ cells (spleen)↑ [124]
Tumor growth (rechallenge)↓
H22 ± tumor lysate vaccine Cytolytic activity (spleen)↑ [121]
Tumor growth (rechallenge)↓
∗NK cell phenotype was not speciﬁed.
However, survival was not diﬀerent between the vaccination
groups [121]. In another model, the same group utilized
a DC vaccine loaded with cell debris from HIFU-treated
or -untreated tumor cells. While tumor growth was again
reduced, no survival advantage could be observed. However,
increased activity of CD8+ splenocytes could be detected
in IFNγ ELISPOT [124] .T h e s ew e r es u p p o r t e db yin vitro
experimentsshowingactivationofbone-marrowderivedDC
upon incubation with tumor lysates and increased tumor
killing by splenocytes harvested from HIFU-treated animals
[121].
In contrast, several studies describe increased numbers
of peripheral T cells following HIFU, which did not exert
enhanced antitumor immunity [123, 125, 126].
Several groups observed a loss in tumor antigen expres-
sion in ablated prostate [23] or breast carcinoma [147,
148] lesions after HIFU. Such downregulation would be
expected to lead to a reduced recognition of tumor tissue
through antigen-speciﬁc T cells. Further investigations will
be needed to determine whether the HIFU method is
generally appropriate for eﬃcient induction of antitumor T-
cell immunity in patients.
6. Laser Ablation
Laser-induced thermotherapy (LITT) is applied widely for
photocoagulation in retinal diseases, where the release of
proinﬂammatory cytokines [127] or the activation of retina-
speciﬁc T cells after panretinal photocoagulation (PRP)
[149] have been described. In cancer patients, however, laser
ablation is still experimental, and only scarce publications
haveaddressedthemodulationofcellularimmunitythrough
LITT (Table 6).
6.1. Cytokines and Stress Response. In patients, laser ablation
led to increased levels of IL-6 and TNF-receptor 1 in the
serum of patients suﬀering from primary and secondary
malignant lesions of the liver 72 hours after treatment.
Changes in the level of other proinﬂammatory cytokines
such as TNF and IL-1β were not observed in this study [130].
In a murine model of colorectal liver metastases, LITT
was also shown to enhance expression of HSP-70 at the mar-
gin of the coagulated tissue, with cytoplasmic and nuclear
expression in sublethally damaged mouse hepatocytes and
extraparenchymal cells. In tumor cells, this upregulation wasClinical and Developmental Immunology 13
Table 6: Studies reporting immune modulation in cancer patients and animal models treated with LITT.
Species Tumor Model Immunologic Eﬀect References
Human CRC (n = 4) IL-6, TNF-R1 (serum)↑ [130]
HCC (n = 3)
Other (n = 6)
Mouse (CBA) Liver metastases of CRC MoCR HSP-70 (cytoplasm, nuclear)↑ [131]
Subcutaneous CRC tumors MoCR CD3+ cells (tumor-host interface)↑ [132]
Spontaneous IFNγ production (spleen, lymph nodes, tumor,
and distant tumors)↑
Rat (WAG) CRC CC531 CD8, CD86, MHC-II, CD11a, and ICAM1 expression (invasion [128]
front of distant tumors)↑
detectedbetween12hoursand7daysafterintervention,with
ap e a ka t2 4h o u r s[ 131].
6.2. Cellular Immunity. In WAG rats, Isbert and colleagues
induced two independent tumors in the left and right liver
lobes. One of the two tumors was either ablated with LITT
or surgically removed, and immune cell inﬁltration into the
untreated remaining tumor was compared to that observed
in an untreated control group. Expression of CD8, CD86,
MHC-class II, and adhesion molecules was found to be
increased between 1 and 10 days after LITT at the tumor
invasion front as compared to resection or no treatment,
indicating an inﬂux of immune cells [128]. Moreover, the
growthoftheuntreatedtumorswasfoundtobeconsiderably
reduced in LITT-treated animals.
Using a murine CRC model, Lin and coworkers observed
an increased inﬁltration of CD3+ T cells into the tumor-
host interface and into the tumor, as well as into the liver
parenchyma and—to a certain extent—also into distant
tumor lesions. Moreover, increased activation of splenocytes
and tumor inﬁltrating lymphocytes was reported in ex vivo
IFNγ ELISPOT without antigen restimulation [132]. Of
note, these results were all obtained in animal models, and
immune modulation after LITT has not been reported for
cancer patients yet.
Taken altogether, the available results strongly suggest
that laser therapy, as shown for other thermoablation
methods, can stimulate antitumor immune eﬀector cells in
vivo [128, 132].
7. Conclusion andPerspectives:Implications
for Anticancer Therapy
During the past two decades, numerous publications in
animal models and patients have shown that local ther-
moablative techniques can induce or enhance tumor-
speciﬁc immune responses that contribute to tumor control.
Although the sequential mechanisms involved are not yet
fully elucidated, several pieces of the puzzle have been
identiﬁed: thermal treatment induces necrosis and can (i)
lead to local inﬂammation, release of danger signals—
for example, heat shock proteins—which may even been
detected systemically; (ii) stimulate the recruitment and
activation of immune eﬀector cells, including DC, at the
vicinity and most probably inside the damaged tumoral
tissue. Both processes occur rapidly, that is, within a few
hours to days following intervention; (iii) activate antitumor
adaptive immunity, including CD4+,C D 8 + T cells, and
antibody production which can contribute to local tumor
elimination, control distant tumors including micrometas-
tases, and establish long lasting antitumor immunological
memory [69, 72, 83, 93, 97, 121]. The source of tumor-
associated antigens for inducing speciﬁc T cells may be either
necrotic dying cells [138, 150, 151] or sublethally damaged
cells [62, 63]. Besides these direct mechanisms, the removal
of tumor tissue leads to depletion of Treg and more generally
may overcome local immunosuppression shifting favorably
the balance towards eﬀective antitumor immunity [61, 96,
105].
Hence,thermoablationcantriggerphysiologicalcascades
necessary and suﬃcient for a protective immune response.
Obviously, several methods can be applied successfully,
suggesting that the key element is the induction of local
necrosis, which can be achieved by using diﬀerent settings
and temperatures. High temperatures (RF ablation, MWA,
HIFU, and LITT) seem rather to sustain antitumor activity
whereas both immunomodulatory and immunosuppressive
eﬀects have been reported upon cryoablation. Of note, the
lesions induced by high-temperature thermoablation are
probably not solely of necrotic nature but may also exhibit
apoptoticcells[16,152,153].Whetheroppositeimmunolog-
icaloutcomesarehencerelatedtoadiﬀerentbalancebetween
apoptosis, necrosis, and secondary necrosis, with apoptotic
cells acting more in a tolerizing or immunosuppressive
fashion and necrotic cells more immunogenic, is at the
moment unclear [138, 139]. Because necrosis induction
can be easily visualized during thermoablative intervention,
controlled necrosis might be an ideal tool for inducing
enhanced immunogenic cell death [154]. Interestingly, local
hyperthermia between 40◦Ca n d4 4 ◦C has been also been
described to modulate immunity, as reviewed elsewhere
[155].
However, it should be noted that the reported eﬀects of
thermoablation alone on the immune system are generally
modest, suggesting that such treatment as a monotherapy
is in general not capable of inducing suﬃcient immune
responses for full tumor protection [97, 118]. Thermother-
apy should be therefore most eﬀective in case of a limited14 Clinical and Developmental Immunology
tumor burden, ideally without detectable tumor postin-
terventionally, and not in advanced cancer where it is
applied in most cases so far. Notably, combined therapies in
order to enhance tumor-speciﬁc immune responses showed
extremely promising results. Several strategies, such as check
point blockade (anti-CTLA-4 mAb, Treg depletion) [69]o r
application of adjuvants (interleukins or chemokines, GM-
CSF,TLRagonists)havebeenevaluatedinpreclinicalmodels
but very little in clinical application yet. Randomized trials
have still to be conducted.
In summary, thermal ablation represents a promising
component for cancer immunotherapy in the treatment of
small or subclinical tumor lesions which can be attacked
by the patient’s immune system. By controlled induction
of physiological stress, it oﬀers the possibility of letting the
“natural” immune response develop in its whole by breaking
self-tolerance. So, thermal ablation of cancer provides a
therapeutic implementation of the danger model.H o w e v e r ,
the induced antitumor immunity is weak and probably not
suﬃcient alone to eradicate established tumors, but it can
synergize with some chemotherapies and immunomodu-
lating strategies. Selecting the appropriate thermoablative
method and ﬁnding optimal combinations for individual
patients will be an exciting challenge for the upcoming years.
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US Ultrasound.
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